Investology Reiterates Positive Rating on USA Technologies
MALVERN, Pa, April 10, 2006 -- Investology, ranked as the #3 best performing independent research firm by BusinessWeek magazine in 2004, reiterated its Positive Rating on USA Technologies (OTCBB: USAT). The report was issued by Waheed Hassan, CFA.
Mr. Hassan has worked as Senior Research analyst with Indsuez W.I. Carr Securities, UBS Warburg, and an affiliate of Merrill Lynch. He was rated amongst #1 Financial Sector research analysts in The Reuters Survey of Global Emerging Markets 1998. Similarly, he was a member of the #1 rated research team according to The Reuters Survey of Global Emerging Markets 1999 and Euromoney Awards for Excellence 2000. He is a member of the CFA Institute.
The entire report is available at www.investologyinc.com/paid.asp.
Investology was started with the sole objective of providing institutional investors with unbiased, objective research. Investology's Research team focuses on six industry sectors: Financial Services, Real Estate, Technology, Healthcare, Energy, and Diversified Industrials. The firm focuses on micro-cap and small-cap stocks, which lack coverage by traditional research firms or investment banks. Investology Inc. The firm is headquartered in Virginia, with offices in New York and Toronto, Canada. Investology Research was ranked as the # 3 best performing independent research firm by BusinessWeek magazine in 2004, and was featured in the Entrepreneur magazine in 2005. Investology Research is distributed through major platforms such as First Call, Zacks.com and Bloomberg.
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product acceptance, the ability to continually obtained increased orders of its products, the ability to meet installation goals, economic, competitive, governmental impacts, whether its pending patents will be granted or defendable; validity of intellectual property and patents of USA, the ability of USA to license its patents, the ability of USA to commercialize its developmental products, technological and/or other factors, which could cause actual results or revenues to differ materially from those contemplated by these statements.